15 August 2023 Xiamen, China——Amoy Diagnostics Co., Ltd (AmoyDx SZSE: 300685) today announces that it has entered into a new collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN).
Based on the agreement, the AmoyDx® Essential NGS panel, developed by AmoyDx, will be used as a companion diagnostic of ENHERTU® to identify HER2 (ERBB2) mutations in patients with non-small cell lung cancer (NSCLC).
ENHERTU® is a HER2-directed antibody-drug conjugate (ADC), jointly developed and commercialized by AstraZeneca and Daiichi Sankyo (TSE: 4568). In China, ENHERTU is approved to treat patients with previously treated HER2-low and HER2-positive metastatic breast cancer. In other countries, ENHERTU is also approved to treat patients with HER2-positive metastatic gastric cancer and HER2 (ERBB2) mutant metastatic NSCLC. This new agreement further expands the cooperation between the companies with projects in prostate, breast cancer and ovarian cancer ongoing.
As a leading company in oncology companion diagnostics whose headquarters are based in China, AmoyDx has a number of companion diagnostic programs aligned to our partners’ innovative drug development programs. Li-Mou Zheng, PhD, Founder and Chairman of AmoyDx, commented: “We are delighted to expand our companion diagnostic collaboration with AstraZeneca. Having the right companion diagnostic tool to identify patients who may benefit from innovative therapies is critical. Through this collaboration, we hope to further our understanding of HER2 mutations and support the development of ENHERTU for lung cancer patients in China.”
We will continue to work with our pharmaceutical partners in the development of precision oncology diagnostic tests to identify those patients that will benefit from targeted treatments, bringing more, and better precision oncology products into the clinic in order to maximise patient benefit.